DK175022B1 - Fremgangsmåde til fremstilling af en morfologisk homogen polymorf af Famotidin form B - Google Patents
Fremgangsmåde til fremstilling af en morfologisk homogen polymorf af Famotidin form B Download PDFInfo
- Publication number
- DK175022B1 DK175022B1 DK198704041A DK404187A DK175022B1 DK 175022 B1 DK175022 B1 DK 175022B1 DK 198704041 A DK198704041 A DK 198704041A DK 404187 A DK404187 A DK 404187A DK 175022 B1 DK175022 B1 DK 175022B1
- Authority
- DK
- Denmark
- Prior art keywords
- famotidine
- solution
- data
- preparing
- salt
- Prior art date
Links
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical group NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 title claims description 29
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 229960001596 famotidine Drugs 0.000 claims description 26
- 239000013078 crystal Substances 0.000 claims description 14
- 238000002844 melting Methods 0.000 claims description 14
- 230000008018 melting Effects 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 9
- 230000000877 morphologic effect Effects 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000002329 infrared spectrum Methods 0.000 claims description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 4
- 239000000908 ammonium hydroxide Substances 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 229940127557 pharmaceutical product Drugs 0.000 claims description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 15
- 238000003756 stirring Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000000113 differential scanning calorimetry Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- WCASXYBKJHWFMY-NSCUHMNNSA-N 2-Buten-1-ol Chemical compound C\C=C\CO WCASXYBKJHWFMY-NSCUHMNNSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- WCASXYBKJHWFMY-UHFFFAOYSA-N gamma-methylallyl alcohol Natural products CC=CCO WCASXYBKJHWFMY-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012536 packaging technology Methods 0.000 description 1
- 238000001144 powder X-ray diffraction data Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- -1 steroid compounds Chemical class 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU337086 | 1986-08-05 | ||
| HU863370A HU196775B (en) | 1986-08-05 | 1986-08-05 | Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK404187D0 DK404187D0 (da) | 1987-08-03 |
| DK404187A DK404187A (da) | 1988-02-06 |
| DK175022B1 true DK175022B1 (da) | 2004-04-26 |
Family
ID=10963778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK198704041A DK175022B1 (da) | 1986-08-05 | 1987-08-03 | Fremgangsmåde til fremstilling af en morfologisk homogen polymorf af Famotidin form B |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US4894459A (cs) |
| EP (1) | EP0256747B2 (cs) |
| JP (2) | JP2644234B2 (cs) |
| KR (1) | KR940003954B1 (cs) |
| CN (1) | CN1024275C (cs) |
| AR (1) | AR243175A1 (cs) |
| AT (1) | ATE82274T1 (cs) |
| AU (1) | AU604040B2 (cs) |
| BG (1) | BG60496B2 (cs) |
| CA (1) | CA1265809A (cs) |
| CS (1) | CS268188B2 (cs) |
| DE (2) | DE3782576T3 (cs) |
| DK (1) | DK175022B1 (cs) |
| FI (1) | FI89917C (cs) |
| GR (1) | GR871216B (cs) |
| HU (1) | HU196775B (cs) |
| PH (1) | PH24069A (cs) |
| PT (1) | PT85473B (cs) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO882037L (no) * | 1987-06-22 | 1988-12-23 | Marga Para La Investigacion Sa | Famotidin, polymerte former og fremstilling derav. |
| ES2162867T3 (es) * | 1993-07-09 | 2002-01-16 | Scherer Corp R P | Metodo de fabricacion de formas de dosificacion de farmacos liofilizados. |
| US6939873B2 (en) * | 2000-07-26 | 2005-09-06 | Taro Pharmaceuticals Industries Limited | Non-sedating barbituric acid derivatives |
| US6756379B2 (en) | 2001-07-26 | 2004-06-29 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
| US7683071B2 (en) * | 2000-07-26 | 2010-03-23 | Taro Pharmaceuticals Industries Ltd. | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
| TWI353979B (en) * | 2002-04-10 | 2011-12-11 | Nippon Zoki Pharmaceutical Co | Novel crystal form of 5-hydroxy-1-methylhydantoin |
| CA2426122A1 (en) * | 2002-05-02 | 2003-11-02 | M/S Tonira Pharma Limited | A process for the preparation of a combination of famotidine polymorphis a and b |
| TW200409746A (en) * | 2002-07-26 | 2004-06-16 | Theravance Inc | Crystalline β2 adrenergic receptor agonist |
| EP2156839A1 (en) | 2002-12-11 | 2010-02-24 | Taro Pharmaceutical Industries Ltd. | Method of treating movement disorders using barbituric acid derivatives |
| TW200510277A (en) * | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
| WO2006003651A2 (en) * | 2004-07-02 | 2006-01-12 | Taro Pharmaceutical Industries, Ltd | A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid |
| US20080021078A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
| US8067451B2 (en) * | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
| US20070043097A1 (en) * | 2005-07-18 | 2007-02-22 | Horizon Therapeutics, Inc. | Medicaments containing famotidine and ibuprofen and administration of same |
| US20080020040A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Unit dose form for administration of ibuprofen |
| US8067033B2 (en) | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
| CA2657928C (en) | 2006-07-18 | 2014-12-02 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
| WO2008027963A2 (en) * | 2006-08-31 | 2008-03-06 | Horizon Therapeutics, Inc. | Nsaid dose unit formulations with h2-receptor antagonists and methods of use |
| US8039461B1 (en) | 2006-11-10 | 2011-10-18 | Pisgah Laboratories, Inc. | Physical states of a pharmaceutical drug substance |
| US7718649B1 (en) | 2006-11-10 | 2010-05-18 | Pisgah Labs, Inc. | Physical states of a pharmaceutical drug substance |
| EP2081576A4 (en) * | 2006-11-14 | 2010-06-30 | Taro Pharmaceuticals North Ame | METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES |
| US8883863B1 (en) | 2008-04-03 | 2014-11-11 | Pisgah Laboratories, Inc. | Safety of psuedoephedrine drug products |
| TW201011043A (en) * | 2008-06-20 | 2010-03-16 | Chugai Pharmaceutical Co Ltd | Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives |
| WO2015163832A1 (en) | 2014-04-25 | 2015-10-29 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | An ibuprofen and famotidine combined composition having improved stability |
| TR201618765A2 (tr) | 2016-12-16 | 2018-07-23 | Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi | Ağrı ve enflamasyonun tedavisi için steroid olmayan anti-enflamatuvar ilaçlar ve H2 reseptörü antagonisti kombinasyonları. |
| WO2022015784A1 (en) | 2020-07-15 | 2022-01-20 | Schabar Research Associates Llc | Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1543238A (en) * | 1976-09-21 | 1979-03-28 | Smith Kline French Lab | Polymorph of cimetidine |
| JPS6056143B2 (ja) * | 1979-08-02 | 1985-12-09 | 山之内製薬株式会社 | アミジン誘導体ならびにその製造法 |
| JPS5655383A (en) * | 1979-10-12 | 1981-05-15 | Yamanouchi Pharmaceut Co Ltd | Amizine derivative and its preparation |
| HU185457B (en) * | 1981-09-25 | 1985-02-28 | Richter Gedeon Vegyeszet | Process for preparating cimetidine-z |
| US4496737A (en) * | 1982-09-27 | 1985-01-29 | Merck & Co., Inc. | Process for preparing sulfamylamidine antisecretory agents |
| JPS59227870A (ja) * | 1983-06-07 | 1984-12-21 | Yamanouchi Pharmaceut Co Ltd | 新規２−グアニジノチアゾリン誘導体ならびにその製造法 |
| HU194845B (en) * | 1985-09-11 | 1988-03-28 | Richter Gedeon Vegyeszet | Process for production of n-sulphamil-3-/2-guanidintiazolil-4-methil-tio/-propion-amidin |
| DE3644246A1 (de) * | 1986-06-20 | 1987-12-23 | Uriach & Cia Sa J | Verfahren zur herstelung von 3-(((2-((aminoiminomethyl)-amino)-4-thiazolyl)-methyl)-thio)-n-(aminosulfonyl)-propanimidamid |
| GB8618847D0 (en) * | 1986-08-01 | 1986-09-10 | Smith Kline French Lab | Pharmaceutical formulations |
| NO882037L (no) * | 1987-06-22 | 1988-12-23 | Marga Para La Investigacion Sa | Famotidin, polymerte former og fremstilling derav. |
-
1986
- 1986-08-05 HU HU863370A patent/HU196775B/hu unknown
-
1987
- 1987-07-29 GR GR871216A patent/GR871216B/el unknown
- 1987-07-30 PH PH35602A patent/PH24069A/en unknown
- 1987-08-03 PT PT85473A patent/PT85473B/pt unknown
- 1987-08-03 FI FI873346A patent/FI89917C/fi not_active IP Right Cessation
- 1987-08-03 DK DK198704041A patent/DK175022B1/da not_active IP Right Cessation
- 1987-08-04 AR AR87308333A patent/AR243175A1/es active
- 1987-08-04 CA CA000543728A patent/CA1265809A/en not_active Expired - Lifetime
- 1987-08-04 DE DE3782576T patent/DE3782576T3/de not_active Expired - Lifetime
- 1987-08-04 AT AT87306882T patent/ATE82274T1/de not_active IP Right Cessation
- 1987-08-04 EP EP87306882A patent/EP0256747B2/en not_active Expired - Lifetime
- 1987-08-04 CS CS875799A patent/CS268188B2/cs not_active IP Right Cessation
- 1987-08-04 US US07/081,423 patent/US4894459A/en not_active Expired - Lifetime
- 1987-08-04 CN CN87105373A patent/CN1024275C/zh not_active Expired - Lifetime
- 1987-08-04 JP JP62193855A patent/JP2644234B2/ja not_active Expired - Lifetime
- 1987-08-04 AU AU76542/87A patent/AU604040B2/en not_active Expired
- 1987-08-04 DE DE198787306882T patent/DE256747T1/de active Pending
- 1987-08-04 KR KR1019870008563A patent/KR940003954B1/ko not_active Expired - Fee Related
-
1990
- 1990-04-27 US US07/515,191 patent/US5120850A/en not_active Expired - Lifetime
-
1991
- 1991-07-11 US US07/728,805 patent/US5128477A/en not_active Expired - Lifetime
-
1994
- 1994-01-18 BG BG098384A patent/BG60496B2/bg unknown
- 1994-08-22 JP JP6196865A patent/JP2708715B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK175022B1 (da) | Fremgangsmåde til fremstilling af en morfologisk homogen polymorf af Famotidin form B | |
| KR20240047402A (ko) | 라니피브라노르의 결정형, 이의 제조 방법 및 이의 용도 | |
| UA78295C2 (en) | Micronized crystalline thiopropium bromide | |
| JP7466642B2 (ja) | レンバチニブメシル酸塩結晶形ｘｉ及びその調製方法 | |
| CN108341818A (zh) | 巴瑞克替尼及其磷酸盐的新晶型及其制备方法 | |
| JP2022525125A (ja) | ブレイアコニチンａのｅ結晶形及びその製造方法と応用 | |
| CN116041351B (zh) | 盐酸咪达唑仑新晶型及其制备方法 | |
| CN110372576A (zh) | 一种钙通道阻滞药物分子共晶体及其制备方法 | |
| CN105820157A (zh) | 一种盐酸维拉佐酮晶型及其制备方法 | |
| CN114644681B (zh) | 一种奈玛特韦异丙醇溶剂化物晶型及其制备方法 | |
| FI82457B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbar kristallform çaçav 1-benzhydyl-4 -allylpiperazindihydroklorid. | |
| JP2025518974A (ja) | ルパチフェンフマル酸塩結晶形ｃ、並びにその調製方法及び使用 | |
| CN110582279A (zh) | 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物 | |
| CA2591670A1 (en) | Process of preparing ziprasidone mesylate | |
| RU2737721C2 (ru) | Способ получения фармацевтической субстанции на основе пирибедила | |
| CN110384673A (zh) | 右旋奥拉西坦胶囊及其制备方法 | |
| HK40078336A (en) | Anticancer compositions | |
| EP1180022A1 (en) | Process for preparing pharmaceutical bulk material having uniform dissolution | |
| CN105168176A (zh) | 一种血管扩张药物盐酸法舒地尔组合物胶囊 | |
| CN105055332A (zh) | 一种治疗缺血性脑血管疾病的药物盐酸法舒地尔组合物干混悬剂 | |
| CN105125500A (zh) | 治疗缺血性脑血管病的药物盐酸法舒地尔组合物干混悬剂 | |
| CN105055425A (zh) | 一种治疗脑缺血的药物盐酸法舒地尔组合物颗粒剂 | |
| CN105125561A (zh) | 一种治疗脑血管疾病的盐酸法舒地尔组合物冻干粉针剂 | |
| CN105193711A (zh) | 一种治疗脑血管疾病的药物盐酸法舒地尔组合物水针剂 | |
| CN105078916A (zh) | 一种止吐药物盐酸托烷司琼组合物片剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |